Eckert & Ziegler Reports Q1 2025 Revenue Growth and Upholds Yearly Outlook

In the first quarter of 2025, Eckert & Ziegler SE reported a revenue increase to €68.2 million, up €0.6 million from the previous year, despite challenges like a February cyber attack and disruptions in gallium generator deliveries. The company's EBIT before special items rose by 8% to €16.2 million, while net income grew by 14% to €9.7 million, equivalent to €0.46 per share.

The group's Medical segment maintained stable sales at €34.4 million, while the Isotope Products segment saw a slight increase, achieving €33.8 million in revenue. The Executive Board confirmed the full-year 2025 forecast, expecting sales of around €320 million and an adjusted EBIT of approximately €78 million.

Eckert & Ziegler continues leveraging its expertise in isotope-related components in nuclear medicine and radiation therapy to drive its financial performance.